| Daniel Wilford Broadbent, MD | |
|
991 Shepard Ln, Ste 200, Farmington, UT 84025-2972 | |
| (801) 397-6080 | |
| (801) 397-6081 |
| Full Name | Daniel Wilford Broadbent |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 15 Years |
| Location | 991 Shepard Ln, Farmington, Utah |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1699901231 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 9314408-1205 (Utah) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Davis Hospital And Medical Center | Layton, UT | Hospital |
| Mckay Dee Hospital | Ogden, UT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ogden Clinic Pc | 9638078033 | 88 |
News Archive
Emergent BioSolutions Inc. today announced that, in response to solicitation RFP-2011-N-13414, it has received an award to supply the U.S. government with 44.75 million doses of BioThrax (Anthrax Vaccine Adsorbed) over a period of five years for a total value of up to $1.25 billion.
Right now, options are limited for preventing heart attacks. However, the day may come when treatments target the heart attack gene, myeloid related protein-14 (MRP-14, also known as S100A9) and defang its ability to produce heart attack-inducing blood clots, a process referred to as thrombosis.
The American Cancer Society, the largest non-government, not-for-profit funding source of cancer research in the United States, has awarded 100 national research and training grants totaling more than $45.6 million in the first of two grant cycles for 2015.
Australian pharmaceutical company Pharmaxis Ltd and UK biotechnology company Synairgen plc today announced they have entered into a research collaboration to develop a selective inhibitor to the lysyl oxidase type 2 enzyme (LOXL2) to treat the fatal lung disease idiopathic pulmonary fibrosis (IPF).
While aspirin has been shown to be effective in preventing heart attacks in men, it also increases the risk of gastrointestinal bleeding and possibly stroke, even at low doses. As such, national guidelines suggest that aspirin be used for prevention only in men at higher risk for cardiovascular events, so that the benefits of aspirin are greater than its adverse effects.
› Verified 3 days ago
| Entity Name | Ogden Clinic Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578550083 PECOS PAC ID: 9638078033 Enrollment ID: O20040105000780 |
News Archive
Emergent BioSolutions Inc. today announced that, in response to solicitation RFP-2011-N-13414, it has received an award to supply the U.S. government with 44.75 million doses of BioThrax (Anthrax Vaccine Adsorbed) over a period of five years for a total value of up to $1.25 billion.
Right now, options are limited for preventing heart attacks. However, the day may come when treatments target the heart attack gene, myeloid related protein-14 (MRP-14, also known as S100A9) and defang its ability to produce heart attack-inducing blood clots, a process referred to as thrombosis.
The American Cancer Society, the largest non-government, not-for-profit funding source of cancer research in the United States, has awarded 100 national research and training grants totaling more than $45.6 million in the first of two grant cycles for 2015.
Australian pharmaceutical company Pharmaxis Ltd and UK biotechnology company Synairgen plc today announced they have entered into a research collaboration to develop a selective inhibitor to the lysyl oxidase type 2 enzyme (LOXL2) to treat the fatal lung disease idiopathic pulmonary fibrosis (IPF).
While aspirin has been shown to be effective in preventing heart attacks in men, it also increases the risk of gastrointestinal bleeding and possibly stroke, even at low doses. As such, national guidelines suggest that aspirin be used for prevention only in men at higher risk for cardiovascular events, so that the benefits of aspirin are greater than its adverse effects.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Daniel Wilford Broadbent, MD Po Box 5546, Denver, CO 80217-5546 Ph: (801) 397-6080 | Daniel Wilford Broadbent, MD 991 Shepard Ln, Ste 200, Farmington, UT 84025-2972 Ph: (801) 397-6080 |
News Archive
Emergent BioSolutions Inc. today announced that, in response to solicitation RFP-2011-N-13414, it has received an award to supply the U.S. government with 44.75 million doses of BioThrax (Anthrax Vaccine Adsorbed) over a period of five years for a total value of up to $1.25 billion.
Right now, options are limited for preventing heart attacks. However, the day may come when treatments target the heart attack gene, myeloid related protein-14 (MRP-14, also known as S100A9) and defang its ability to produce heart attack-inducing blood clots, a process referred to as thrombosis.
The American Cancer Society, the largest non-government, not-for-profit funding source of cancer research in the United States, has awarded 100 national research and training grants totaling more than $45.6 million in the first of two grant cycles for 2015.
Australian pharmaceutical company Pharmaxis Ltd and UK biotechnology company Synairgen plc today announced they have entered into a research collaboration to develop a selective inhibitor to the lysyl oxidase type 2 enzyme (LOXL2) to treat the fatal lung disease idiopathic pulmonary fibrosis (IPF).
While aspirin has been shown to be effective in preventing heart attacks in men, it also increases the risk of gastrointestinal bleeding and possibly stroke, even at low doses. As such, national guidelines suggest that aspirin be used for prevention only in men at higher risk for cardiovascular events, so that the benefits of aspirin are greater than its adverse effects.
› Verified 3 days ago
Dr. David Allen Vandemerwe, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 444 W Bourne Cir, Farmington, UT 84025 Phone: 801-773-4840 Fax: 801-525-8151 | |
Daniel H Chappell, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 991 Shepard Ln, Suite 200, Farmington, UT 84025 Phone: 801-397-6080 Fax: 801-397-6081 | |
Ziyi Wang, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 444 W Bourne Cir Ste 101, Farmington, UT 84025 Phone: 801-294-9333 Fax: 801-294-7558 | |
Mr. Hans C Jenkins, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 722 Shepard Ln, Suite 102, Farmington, UT 84025 Phone: 385-988-3965 Fax: 385-988-3972 | |
Spencer David Cline, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 444 W Bourne Cir, Farmington, UT 84025 Phone: 801-773-4840 Fax: 801-525-8151 | |
Julie C Hibbard, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 1401 N 1075 W, Suite 220, Farmington, UT 84025 Phone: 801-451-4538 Fax: 801-451-2295 |